Anti tumor potential of 3-Aza cyclopenta[α]indene alone or in combination with PI3 kinase inhibitor

博士 === 國立陽明大學 === 生化暨分子生物研究所 === 100 === BO-1090, BO-1100, BO-1130 and BO-1131 are the derivatives of 3a-aza-cyclopenta[a]indene, a class of newly synthesized alkylating agents. In my present study, I demonstrated that novel derivatives may be drugs more specific for oral cancer based on its potent...

Full description

Bibliographic Details
Main Authors: Kumar Sanjiv, 薩克瑪
Other Authors: Te-Chang Lee
Format: Others
Language:en_US
Published: 2011
Online Access:http://ndltd.ncl.edu.tw/handle/08206086649651149556
id ndltd-TW-100YM005107002
record_format oai_dc
spelling ndltd-TW-100YM0051070022015-10-14T04:07:11Z http://ndltd.ncl.edu.tw/handle/08206086649651149556 Anti tumor potential of 3-Aza cyclopenta[α]indene alone or in combination with PI3 kinase inhibitor 3-Aza cyclopenta[α]indene單獨或與PI3激酶抑制劑合併使用之抗癌活性 Kumar Sanjiv 薩克瑪 博士 國立陽明大學 生化暨分子生物研究所 100 BO-1090, BO-1100, BO-1130 and BO-1131 are the derivatives of 3a-aza-cyclopenta[a]indene, a class of newly synthesized alkylating agents. In my present study, I demonstrated that novel derivatives may be drugs more specific for oral cancer based on its potent in vitro cytotoxicity to oral cancer cells and on invivo xenografts. Among all, BO-1090 is the most potent and targeted DNA for its cytotoxic effects as shown by inhibition of DNA synthesis (bromodeoxyuridine-based DNA synthesis assay), induction of DNA crosslinking (alkaline gel shift assay), and induction of DNA single-stranded breaks (Comet assay) and double-stranded breaks (γ-H2AX focus formation). Intravenous injection of BO-1090 significantly suppressed SAS or Cal27 subcutaneous xenografted and orthotopic implanted tumor growth in mice in comparison to control mice. In preliminary drug combination studies when lung cancer cells were treated with BO-1509, a new modified derivative of BO-1012 (derivative of 3a-aza-cyclopenta[a]indene) lead to activation of survival and DNA repair protein that may cause resistance of BO-1509 in tumor cells. To overcome activation of survival and DNA repair protein, I combined BO-1509 with PI3 kinase inhibitor LY294002, which has property to suppress survival and repair pathway. Synergism was found between two drugs in several lung cancer cells including H460, CL-1-5, CL-25 and CL-83 in culture. In CL-1-5 and H460 xenografted mice, LY294002 in combination with BO-1509 significantly suppress the growth of tumor in comparison to the vehicle treated control mice and BO-1509 alone treated mice. Based on γH2AX foci formation assay, half of double strand break (DSB) in cell induced by BO-1509 was repaired by 72 h, while cells treated in combination of BO-1509 with PI3 kinase inhibitor still maintain DSB damage, this suggests the DNA repair inhibition by LY294002 in combination treatment. Initial finding also suggests that synergism between BO-1509 and LY294002 inhibitor may be due to inhibitory effect of LY294002 on Mre11 and Nbs1 proteins of MRN complex, which play important role in homologous DNA repair pathway. In conclusion derivatives of 3a-aza-cyclopenta[a]indene have therapeutic potential either alone i.e. monotherapy of BO-1090 for oral cavity cancer treatment or in combination of BO-1509 with PI3 inhibitor in lung cancer. Te-Chang Lee 李德章 2011 學位論文 ; thesis 123 en_US
collection NDLTD
language en_US
format Others
sources NDLTD
description 博士 === 國立陽明大學 === 生化暨分子生物研究所 === 100 === BO-1090, BO-1100, BO-1130 and BO-1131 are the derivatives of 3a-aza-cyclopenta[a]indene, a class of newly synthesized alkylating agents. In my present study, I demonstrated that novel derivatives may be drugs more specific for oral cancer based on its potent in vitro cytotoxicity to oral cancer cells and on invivo xenografts. Among all, BO-1090 is the most potent and targeted DNA for its cytotoxic effects as shown by inhibition of DNA synthesis (bromodeoxyuridine-based DNA synthesis assay), induction of DNA crosslinking (alkaline gel shift assay), and induction of DNA single-stranded breaks (Comet assay) and double-stranded breaks (γ-H2AX focus formation). Intravenous injection of BO-1090 significantly suppressed SAS or Cal27 subcutaneous xenografted and orthotopic implanted tumor growth in mice in comparison to control mice. In preliminary drug combination studies when lung cancer cells were treated with BO-1509, a new modified derivative of BO-1012 (derivative of 3a-aza-cyclopenta[a]indene) lead to activation of survival and DNA repair protein that may cause resistance of BO-1509 in tumor cells. To overcome activation of survival and DNA repair protein, I combined BO-1509 with PI3 kinase inhibitor LY294002, which has property to suppress survival and repair pathway. Synergism was found between two drugs in several lung cancer cells including H460, CL-1-5, CL-25 and CL-83 in culture. In CL-1-5 and H460 xenografted mice, LY294002 in combination with BO-1509 significantly suppress the growth of tumor in comparison to the vehicle treated control mice and BO-1509 alone treated mice. Based on γH2AX foci formation assay, half of double strand break (DSB) in cell induced by BO-1509 was repaired by 72 h, while cells treated in combination of BO-1509 with PI3 kinase inhibitor still maintain DSB damage, this suggests the DNA repair inhibition by LY294002 in combination treatment. Initial finding also suggests that synergism between BO-1509 and LY294002 inhibitor may be due to inhibitory effect of LY294002 on Mre11 and Nbs1 proteins of MRN complex, which play important role in homologous DNA repair pathway. In conclusion derivatives of 3a-aza-cyclopenta[a]indene have therapeutic potential either alone i.e. monotherapy of BO-1090 for oral cavity cancer treatment or in combination of BO-1509 with PI3 inhibitor in lung cancer.
author2 Te-Chang Lee
author_facet Te-Chang Lee
Kumar Sanjiv
薩克瑪
author Kumar Sanjiv
薩克瑪
spellingShingle Kumar Sanjiv
薩克瑪
Anti tumor potential of 3-Aza cyclopenta[α]indene alone or in combination with PI3 kinase inhibitor
author_sort Kumar Sanjiv
title Anti tumor potential of 3-Aza cyclopenta[α]indene alone or in combination with PI3 kinase inhibitor
title_short Anti tumor potential of 3-Aza cyclopenta[α]indene alone or in combination with PI3 kinase inhibitor
title_full Anti tumor potential of 3-Aza cyclopenta[α]indene alone or in combination with PI3 kinase inhibitor
title_fullStr Anti tumor potential of 3-Aza cyclopenta[α]indene alone or in combination with PI3 kinase inhibitor
title_full_unstemmed Anti tumor potential of 3-Aza cyclopenta[α]indene alone or in combination with PI3 kinase inhibitor
title_sort anti tumor potential of 3-aza cyclopenta[α]indene alone or in combination with pi3 kinase inhibitor
publishDate 2011
url http://ndltd.ncl.edu.tw/handle/08206086649651149556
work_keys_str_mv AT kumarsanjiv antitumorpotentialof3azacyclopentaaindenealoneorincombinationwithpi3kinaseinhibitor
AT sàkèmǎ antitumorpotentialof3azacyclopentaaindenealoneorincombinationwithpi3kinaseinhibitor
AT kumarsanjiv 3azacyclopentaaindenedāndúhuòyǔpi3jīméiyìzhìjìhébìngshǐyòngzhīkàngáihuóxìng
AT sàkèmǎ 3azacyclopentaaindenedāndúhuòyǔpi3jīméiyìzhìjìhébìngshǐyòngzhīkàngáihuóxìng
_version_ 1718090309670273024